# A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

> **NCT01711970** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vascular Biogenics Ltd. operating as VBL Therapeutics** · enrollment: 38 (estimated)

## Conditions studied

- Platinum Resistant Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01711970
- **Lead sponsor:** Vascular Biogenics Ltd. operating as VBL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2017-05-03
- **Final completion:** 2017-05-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711970, "A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01711970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*